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Summary. The purpose of this essay is to recall the actions taken globally to improve the viral safety of coagulation factor concentrates, mainly in the years [1985] [1986] [1987] [1988] [1989] [1990] , at a time of confusing and often contradictory information on bloodborne viral infections in multitransfused patients with hemophilia (PWHs). I shall first recall the problem of the transmission and control of the hepatitis viruses, and then that of HIV: not only for temporal reasons, but also because understanding the progress of knowledge on hepatitis and the poor success of the early measures taken to tackle this problem in PWHs is essential to understand how the problem of HIV transmission was ultimately dealt with successfully.
Emergence of the hepatitis problem
Throughout the 1970s, it was recognized that the clinical use of concentrates of factor VIII and FIX made from plasma pooled from several thousands of blood donations, which was the best treatment available at that time for patients with hemophilia (PWHs), was sometimes associated with jaundice, and that viral hepatitis played an important role in causing this side effect of replacement therapy [1] . The first cross-sectional study of liver function tests, published in 1975 [2] , found that, of 91 asymptomatic PWHs, 45% had elevated serum levels of both transaminases, with no additional biochemical markers of severe liver disease. These findings were confirmed in 1977 in a joint UK study, which also demonstrated that high transaminase levels persisted for years [3] . Although non-A non-B viral hepatitis (identified as being caused by hepatitis C virus [HCV] much later, in 1989 [4, 5] ) was suspected to be responsible for these abnormalities, a definite distinction could not be made between transfusion-associated hepatitis and 'transaminitis', i.e. elevations of the levels of these cellular enzymes attributable to non-viral factors (e.g. soft tissue hematomas, drugs used to control pain, and hypersensitivity reactions to allogeneic proteins present in factor concentrates).
Unequivocal evidence of structural liver damage in PWHs was first obtained in 1977. In the framework of a liver biopsy investigation of patients with hemophilia A and chronically elevated transaminase levels, Lesesne et al. [6] diagnosed mild forms of chronic active hepatitis in three, and chronic persistent hepatitis in the remaining three. An important unresolved issue was whether or not chronic hepatitis showed signs of progression. A biopsybased study, published in 1982 and involving 10 PWHs with non-A non-B hepatitis followed up for > 10 years [7] , demonstrated no progression of chronic hepatitis. In 1985, a much larger study of 155 unselected liver biopsies found that histological evidence of progressive disease (including cirrhosis) was present in 22% of PWHs [8] .
The relatively benign picture of non-A non-B hepatitis initially emerging from these studies was questioned by two subsequent reports in 1986 and 1987. Progressive liver disease occurred in approximately one-third of PWHs during a follow-up period of 13 years [9] . In the framework of a prospective study, histological signs of progressive liver disease were found in 20 of 44 biopsies from multitransfused hemophiliacs [10] .
Hence, only in the mid-1970s it had become clear that liver disease was frequent in PWHs, and only in the late 1980s was the disease shown to be progressive in a substantial proportion of cases. Meanwhile, the view held at the time by the great majority of us was that the problem of hepatitis in PWHs was a tolerable one, because patients were asymptomatic, and the benefits of concentrates were outstanding. Furthermore, severe liver disease was not seen in postmortem records as a prominent cause of death in hemophilic patients [11] , the most significant cause still being hemorrhage, particularly intracranial bleeding.
Desmopressin (DDAVP) as an alternative to concentrates
Although, for patients with severe hemophilia, there was little option but to continue the lifesaving concentrate treatment, for patients with mild hemophilia (who bleed infrequently and have little risk of death and disability from bleeding) the risk of bloodborne infections was felt to be less acceptable, and it was with a view to finding alternative treatments for mildly affected patients that DDAVP, a synthetic peptide derived from the antidiuretic hormone vasopressin, was developed. In 1977, we reported that, in 23 patients with mild hemophilia A or von Willebrand disease, DDAVP caused short-term increases in plasma FVIII and von Willebrand factor levels, and was an efficacious prophylactic treatment for bleeding at the time of dental or general surgery [12] . The early use of DDAVP in Italy in the late 1970s to early 1980, at the time of onset of AIDS, was associated with a lower prevalence of HIV infection in patients with mild hemophilia A than in those with mild hemophilia B taken for comparison (being unresponsive to DDAVP, they could only use blood products) and in US patients with mild hemophilia A (who started using DDAVP much later than in Italy) [13] . Plainly, the hemophilia community outside Italy needed some time to seek confirmation of the value of this novel treatment. Accordingly, DDAVP was not used on a relatively large scale until the late 1980s, when the transmission of hepatitis viruses and HIV was largely halted by the advent and adoption of efficacious virucidal methods.
Heat treatment as a virucidal method
The first attempt to treat large-pool plasma-derived concentrates with methods meant to decrease the risk of transmission of hepatitis viruses was made by the industrial manufacturer Biotest, which, in 1982, reported no hepatitis in a small group of normal volunteers infused with a prothrombin complex concentrate in which virus inactivation was achieved by adding the chemical b-propiolactone and applying ultraviolet light [14] . This report raised a number of ethical questions, not only because volunteers were recruited from among the staff of Biotest, but also because b-propiolactone was a potentially carcinogenic compound. Subsequently, another commercial manufacturer (Behring) produced a pasteurized FVIII concentrate, and claimed that this heating procedure, which had previously been used only for albumin, did inactivate the hepatitis viruses. However, the Behring concentrate was not available in the majority of European countries, and it was, indeed, insufficient even to meet the German needs. The German health authorities resisted its widespread use, because the concentrate was two to three times more expensive than unheated products, and its real advantages were uncertain. It was not until a 1987 report by Schimpf et al. [15] that it was convincingly established to be safe regarding the transmission of viral hepatitis.
It was only at the beginning of the 1980s that attempts to validate clinically the methods developed by commercial manufacturers to inactivate or remove the hepatitis viruses and that were applicable to coagulation factor concentrates started on a large scale. The International Committee on Thrombosis and Hemostasis (ICTH) recommended, in November 1984, that only highly susceptible PWHs should be evaluated, i.e. previously untreated (so-called 'virgin') patients [15] . This recommendation was based on the evidence that previously untreated PWHs developed hepatitis with a rate close to 100% after they were first infused with large-pool plasmatic concentrates, and also those made from unpaid donors [16, 17] . A number of studies were conducted adopting these recommendations on the heated coagulation products progressively produced by manufacturers. In 1985, Colombo et al. published the first study carried out under the ICTH rules [18] , and showed that, following the first infusion of a concentrate, heated in the lyophilized state (dry heating) at 60°C for 72 h, as many as 11 of 13 patients did develop non-A non-B hepatitis. In the next few months, other studies evaluated products that had been dry-heated at temperatures varying between 60°C and 68°C for different periods of time (between 24 h and 72 h) or added with n-heptane in the liquid state, but similarly high rates of hepatitis transmission were recorded [19] [20] [21] .
These ineffective early methods were abandoned, and more efficacious methods were soon developed. In the next 3 years (1986-1988), there were several publications indicating that second-generation virucidal methods (dry heating at higher temperatures such as 80°C, pasteurization, vapour heating, and the use of solvent-detergent) plus the subsequent use of transaminase-screened plasma were greatly superior to the early measures with regard to dramatically reducing the incidence of hepatitis after the administration of large-pool plasmatic concentrates.
Hepatitis-safe products
The evidence that plasma-derived concentrates used for the treatment of PWHs became much safer in terms of hepatitis transmission stemmed not only from the results obtained in high-risk previously untreated patients according to the ICTH protocol, but also from the routine surveillance of PWHs, which revealed a paucity of cases of viral hepatitis after 1987. For instance, in the framework of a study published in 1991 and carried out in a cohort of Canadian children with hemophilia treated exclusively with concentrates manufactured with secondgeneration virucidal methods, none developed serological signs of HCV infection, in striking contrast to a 95% infection rate in those treated with untreated or inadequately treated concentrates [22] . In addition, Morfini et al., dealing with 708 PWHs (approximately one-quarter of the whole hemophilic population of Italy), showed that only 6% of those first infused between 1985 and 1991 became infected with HCV, in contrast to the very high rate of infection (83%) in those infused before 1985 [23] . Furthermore, the majority of the infected patients had indeed been treated with concentrates manufactured with first-generation virucidal methods based on inadequate heating methods [23] .
All in all, post-transfusion hepatitis in PWHs was effectively halted in 1987-1988. This success was related not only to the aforementioned continuous improvement of methods used to inactivate or remove viruses, but also to the new measures adopted for donor selection and screening. A major role was certainly played by the isolation and identification in 1989 of the virus (HCV) causing non-A, non-B hepatitis [4] , and the development of a serological test to screen donors (anti-HCV) [5] and its adoption in 1991 to screen plasma destined for fractionation.
HIV infection and AIDS
In 1982 worldwide, there were only two known PWHs with AIDS [24] . In 1983 there were a few more cases, but many of us had not seen a case until 1984 [25] . Moreover, despite the prevailing view that the cause of AIDS was a virus, there were alternative theories. The idea of the immune systems of PWHs being compromised by their sustained exposure to plasma-derived concentrates was looming large, and two articles published in January 1983 in the New England Journal of Medicine [26, 27] showed immunological abnormalities in PWHs transfused with FVIII products, including single-donor cryoprecipitate. It was at the end of 1983 that lymphotropic retroviruses were independently isolated from patients with AIDS by the teams of Gallo and Montagnier [28, 29] , but initially there was no solid demonstration that they were the cause of AIDS rather than being casually associated with it. Anyway, having learnt that the putative retroviral agent of AIDS (lymphadenopathy-associated virus [LAV]) could be easily inactivated by heating [30] , in September 1984 I contacted Montagnier in Paris in order to assay, with a preliminary serological test developed by him, some of the serum samples previously collected from the PWHs enrolled in the study reporting the negative effect of heat treatment on hepatitis [18] . In February 1985, no antibodies against LAV were found in patients treated exclusively with the concentrate heated at 60°C for 72 h [31] , providing the first clinical demonstration that dry heating could effectively inactivate the AIDS-causing virus contaminating clotting factor concentrates.
Although there were earlier proponents of the idea that heating the concentrates should be effective against AIDS, particularly the late Harold Roberts, in 1983 and 1984 there was little evidence that heat treatment would be efficacious against the putative viral agent. In addition, there were concerns about the potential denaturation induced by heating of a labile protein such as FVIII, and the possibility of increased production of antibodies (inhibitors) against FVIII [32] . Furthermore, the failure of the early methods based on dry heating to inactivate the hepatitis virus was a fundamental snag, because it convinced many of us that the method had, in general, little virucidal activity. On the whole, everybody was in doubt in the early 1980s until February 1985, when it was shown that heated concentrates did not transmit the retrovirus that, in the same year, was convincingly shown to be the cause of AIDS.
Conclusions
What is the current situation pertaining to the infectivity of coagulation factor products? Their production by means of recombinant DNA technology from mammalian or human cell lines in culture has been a dramatic step forwards that, from the early 1990s, has reassured the hemophilia community about the safety of coagulation factor products. With the awareness that recombinant DNA technology is a biological process, viral inactivation methods have since been applied by manufacturers even to these products. Solid evidence of current safety also applies to plasma-derived products, owing to the adoption by almost all manufacturers of at least two methods of viral inactivation or removal, which add to the measures implemented to obtain safer and safer plasma sources. The dramatic events that occurred in the 1980s and the theoretical fear of novel forthcoming infectious agents that may be resistant to the current measures still nurture the perception that plasma-derived coagulation factors are less safe than recombinant products [33] . However, the development of FVIII inhibitors has now become by far the major safety issue in the framework of replacement therapy of coagulation factor concentrates: with evidence that plasma-derived products result in less development of inhibitors than recombinant products [34] .
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